Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.
Simple Summary: Targeted therapy has significantly improved outcomes for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, the emergence of resistance remains an inevitable clinical challenge. Standard treatment after progression on third-generation...
| Publicado en: | Current Oncology Vol. 33; no. 5; pp. 258 - 268 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
May2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |